title: Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
abstract: BACKGROUND
  Fludarabine was associated with a good response and was well tolerated in patients with follicular lymphoma in phase II trials and this treatment may be associated with less adverse events than treatment with CHVP plus interferon in elderly patients.
  
  
  METHODS
  One hundred thirty-one patients older than 59 years with a follicular lymphoma and poor prognosis were randomized between the association of CHVP (12 cycles in 18 months) plus interferon (5 MU TIW for 18 months) or fludarabine alone (25 mg/m2/d x 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months). Poor prognosis was defined by the presence of a large tumor mass, poor performance status, the presence of B symptoms, above normal LDH level, or > or = 3 mg/l beta-microglobulin level.
  
  
  RESULTS
  Patients treated with CHVP plus interferon had a higher response to treatment, a longer time to progression and a longer survival than those treated with fludarabine alone (P < 0.05 for all analyses). With a median follow-up of 29 months, the 2-year failure-free survival was 63% for the CHVP-plus-interferon arm compared to 49% for the fludarabine arm and the two-year survival was 77% and 62%, respectively. This benefit was confirmed in a multivariate analysis including initial prognostic parameters. Fludarabine alone was associated with less neutropenia than CHVP plus interferon. Interferon was decreased or stopped in 39% of the patients because of severe fatigue.
  
  
  CONCLUSIONS
  CHVP plus interferon over 18 months was associated with a better outcome, even though the combination of interferon plus chemotherapy was less well tolerated than fludarabine.
authors.affiliation: Hospices Civils de Lyon, France. bertrand.coiffier@chu-lyon.fr
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: E M
authors.initials: EM
authors.lastname: Neidhardt-Bérard
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: C
authors.initials: C
authors.lastname: Belanger
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.forename: P
authors.initials: P
authors.lastname: Brice
authors.forename: P Y
authors.initials: PY
authors.lastname: Péaud
authors.forename: J L
authors.initials: JL
authors.lastname: Pico
authors.forename: M
authors.initials: M
authors.lastname: Janvier
authors.forename: P
authors.initials: P
authors.lastname: Solal-Celigny
authors.forename: N
authors.initials: N
authors.lastname: Brousse
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D016019:Survival Analysis; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D007372:Interferons; D013713:Teniposide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone